173 related articles for article (PubMed ID: 32522063)
1. Novel [(
Al-Warhi T; Abo-Ashour MF; Almahli H; Alotaibi OJ; Al-Sanea MM; Al-Ansary GH; Ahmed HY; Elaasser MM; Eldehna WM; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1300-1309. PubMed ID: 32522063
[TBL] [Abstract][Full Text] [Related]
2. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
4. Development of isatin-thiazolo[3,2-a]benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and molecular dynamics investigations.
Eldehna WM; El Hassab MA; Abo-Ashour MF; Al-Warhi T; Elaasser MM; Safwat NA; Suliman H; Ahmed MF; Al-Rashood ST; Abdel-Aziz HA; El-Haggar R
Bioorg Chem; 2021 May; 110():104748. PubMed ID: 33684714
[TBL] [Abstract][Full Text] [Related]
5. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.
Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM
Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors.
Al-Warhi T; El Kerdawy AM; Aljaeed N; Ismael OE; Ayyad RR; Eldehna WM; Abdel-Aziz HA; Al-Ansary GH
Molecules; 2020 Apr; 25(9):. PubMed ID: 32349307
[TBL] [Abstract][Full Text] [Related]
8. Novel Thiazolidinone/Thiazolo[3,2-
El-Naggar M; Eldehna WM; Almahli H; Elgez A; Fares M; Elaasser MM; Abdel-Aziz HA
Molecules; 2018 Jun; 23(6):. PubMed ID: 29895744
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents.
Eldehna WM; Abo-Ashour MF; Nocentini A; El-Haggar RS; Bua S; Bonardi A; Al-Rashood ST; Hassan GS; Gratteri P; Abdel-Aziz HA; Supuran CT
Eur J Med Chem; 2019 Jan; 162():147-160. PubMed ID: 30445264
[TBL] [Abstract][Full Text] [Related]
10. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
[TBL] [Abstract][Full Text] [Related]
11. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of New CDK2 Inhibitors Containing Thiazolone and Thiazolthione Scafold with Apoptotic Activity.
El-Sattar NEAA; Badawy EHK; AbdEl-Hady WH; Abo-Alkasem MI; Mandour AA; Ismail NSM
Chem Pharm Bull (Tokyo); 2021; 69(1):106-117. PubMed ID: 33390512
[TBL] [Abstract][Full Text] [Related]
13. Development of newly synthesised quinazolinone-based CDK2 inhibitors with potent efficacy against melanoma.
Mohammed ER; Elmasry GF
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):686-700. PubMed ID: 35139719
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM
Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
[TBL] [Abstract][Full Text] [Related]
15. Marine-Inspired Bis-indoles Possessing Antiproliferative Activity against Breast Cancer; Design, Synthesis, and Biological Evaluation.
Eldehna WM; Hassan GS; Al-Rashood ST; Alkahtani HM; A Almehizia A; Al-Ansary GH
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32252280
[TBL] [Abstract][Full Text] [Related]
16. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
El-Naggar AM; El-Hashash MA; Elkaeed EB
Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
[TBL] [Abstract][Full Text] [Related]
17. Development of novel benzofuran-isatin conjugates as potential antiproliferative agents with apoptosis inducing mechanism in Colon cancer.
Eldehna WM; Salem R; Elsayed ZM; Al-Warhi T; Knany HR; Ayyad RR; Traiki TB; Abdulla MH; Ahmad R; Abdel-Aziz HA; El-Haggar R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1424-1435. PubMed ID: 34176414
[TBL] [Abstract][Full Text] [Related]
18. Development of pyrolo[2,3-c]pyrazole, pyrolo[2,3-d]pyrimidine and their bioisosteres as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological evaluation and molecular dynamics investigations.
Azmy EM; Hagras M; Ewida MA; Doghish AS; Gamil Khidr E; El-Husseiny AA; Gomaa MH; Refaat HM; Ismail NSM; Nassar IF; Lashin WH
Bioorg Chem; 2023 Oct; 139():106729. PubMed ID: 37467621
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and SARs study of novel spiro-oxindoles as potent antiproliferative agents with CDK-2 inhibitory activities.
Al-Jassas RM; Islam MS; Al-Majid AM; Nafie MS; Haukka M; Rahman AFMM; Alayyaf AMA; Barakat A
Arch Pharm (Weinheim); 2023 Aug; 356(8):e2300185. PubMed ID: 37253118
[TBL] [Abstract][Full Text] [Related]
20. A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed with Anti-Breast Cancer Activity: Design, Synthesis, Biological Evaluation, and In Silico Insights.
Al-Sanea MM; Obaidullah AJ; Shaker ME; Chilingaryan G; Alanazi MM; Alsaif NA; Alkahtani HM; Alsubaie SA; Abdelgawad MA
Molecules; 2021 Jan; 26(2):. PubMed ID: 33466812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]